PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.
Never miss a new study
Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear
Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Rare overgrowth disorder drug tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug alpelisib in children and adults with PIK3CA-related overgrowth spectrum (PROS), a rare condition that causes abnormal growth. All 41 participants had already taken alpelisib in a previous study. Researchers w…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug shows promise for rare overgrowth disorder in kids and adults
Disease control OngoingThis study tests a drug called alpelisib in children and adults with PROS, a rare condition that causes abnormal growth of body parts. The goal is to see if the drug can shrink these overgrowths by at least 20%. Participants are randomly assigned to receive the drug or a placebo …
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 08, 2026 12:03 UTC